There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry
Recruiting
INSIGHTS is a registry research study that collects key information on medical history for girls and women with Turner syndrome and the clinical care they receive. This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. In addition to learning a lot about the current state of health for individuals with TS, INSIGHTS serves as an infrastructure to conduct future studies are meaningful to patients and their families.
Gender:
FEMALE
Ages:
All
Trial Updated:
09/27/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Turner Syndrome
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing
Recruiting
The overall goal of this study is to map the spatiotemporal dynamics of social affective processing and to examine selective modulation of these dynamics in humans undergoing invasive intracranial monitoring for treatment-resistant epilepsy and depression. Pursuing this signal from a novel platform with invasive intracranial recording electrodes provides much-needed spatial and temporal resolution to characterize the neural dynamics of socio-affective processing. The investigators will leverage... Read More
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
09/27/2024
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Treatment Resistant Depression, Epilepsy
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
Olorofim Aspergillus Infection Study
Recruiting
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Houston Methodist, Houston, Texas
Conditions: Invasive Aspergillosis
Use of Nicotine Pouches Among Daily Smokers
Recruiting
The purpose of this clinical trial is to understand the health effects of a new oral nicotine pouch, and also to understand if this product can help reduce traditional cigarette smoking. The main aims are: 1. Understand the impact of nicotine pouch use on toxicant exposure biomarkers, and indicators of potential harms to health. 2. Examine the influence of nicotine pouch use on conventional tobacco product use (cigarettes). Participants will be randomized to one of six nicotine pouch groups (3... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
09/25/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Tobacco Dependence
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
Recruiting
The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific ai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: Memorial Hermann Texas Medical Center, Houston, Texas
Conditions: Acute Kidney Injury
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: MD Anderson, Houston, Texas
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Effectiveness of Small Phlebotomy Tubes in Reducing Blood Transfusions in Adult Medical Intensive Care Unit and Intermediate Care Unit Patients With Anemia
Recruiting
The purpose of this study is to evaluate the effectiveness of small phlebotomy tubes to reduce RBC transfusions in medical intensive care unit (ICU) and Intermediate care unit (IMU) patients with low hemoglobin compared with standard size tubes, to compare the intervention and the control groups in regards to: ICU length of stay (LOS), ICU mortality, hospital LOS, and hospital mortality and to assess the acceptability of small phlebotomy tubes in adult ICU and IMU patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Anemia
Screening Emotions in Adolescents at the Hospital for mTBI
Recruiting
The goal of this observational study is to develop and validate a clinical tool to predict which adolescents aged 11 to less than 18 years of age with mild traumatic brain injury (mTBI) are at an increased risk for developing significant new or worsening mental health conditions. The main aims the study wish to answer are: * Does the adolescent have new or worsening depression or anxiety defined as a change from their previous medical history using self-reported questionnaires at either one or... Read More
Gender:
ALL
Ages:
Between 11 years and 17 years
Trial Updated:
09/19/2024
Locations: Baylor College of Medicine, Texas Children's Hospital, Houston, Texas
Conditions: Brain Injury Traumatic Mild, Brain Injuries, Brain Injuries, Acute, Head Injury With Intracranial Hemorrhage, Head Injury Trauma, Brain Injury Traumatic Focal With Loss of Consciousness, Skull Fractures, Diffuse Axonal Injury, Intracranial Hemorrhages, Head Injury
Neuroblastoma Maintenance Therapy Trial
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Texas Children's Cancer and Hematology Centers, Houston, Texas
Conditions: Neuroblastoma
Ketorolac in Palatoplasty
Recruiting
The purpose of this study is to see if the addition of IV Ketorolac to usual care multi-modal pain therapy compared to usual care will improve oral intake post-operatively
Gender:
ALL
Ages:
6 months and above
Trial Updated:
09/17/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Cleft Lip and Palate
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Recruiting
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency